Samuel Cusworth

Samuel Cusworth

Auto-generated profile, based on publicly available information

Samuel Cusworth

Department of Applied Health Sciences, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
PQPaola Quattroni
Paola Quattroni
ARAsh Routen
Ash Routen
JAJoe Alderman
Joe Alderman
CAClaire Argent
Claire Argent
SCSamuel Cushworth
Samuel Cushworth
KKKamlesh Khunti
Kamlesh Khunti
The UK Health Data Research Alliance presents five recommendations for improving data collection for inclusive health research.

21 May 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
SCSamuel Cusworth
Samuel Cusworth
ZDZareen Deplano
Zareen Deplano
ADAlastair K Denniston
Alastair K Denniston
DBDavid Burns
David Burns
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar
JCJoht Singh Chandan
Joht Singh Chandan
Introduction Haematological cancers are common in the UK, with a variety of morphologies. Stem cell transplants and chimeric antigen receptor (CAR) T-cell therapies provide significant options for hard to treat haematological cancers, although with difficult to predict outcomes. Research into the determinates of treatment efficacy, and access to treatments, is key to ensuring equal benefit across patients and patient safety. With this, there are concerns about the small representation of minority groups in related research. We aim to report on the current knowledge to guide future research. Methods and analysis A variety of databases will be searched for literature on UK minority ethnic populations receiving haematopoietic stem cell transplant or CAR T-cell therapy. Searches will be restricted to the year 2011 or later. Many outcomes will be analysed, covering the patient care pathway for those of the target population, although with a focus on follow-up after therapy. Plans have been made to conduct narrative synthesis, with meta-analysis where applicable. Ethics and dissemination Ethical approval is not required for this study. Outputs will be published in an appropriate journal and discussed with the wider National Institute for Health and Care Research Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics (BTRU) group. Discussions will also be undertaken with the BTRU patient partners group.

28 February 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
PQPaola Quattroni
Paola Quattroni
ARAsh Routen
Ash Routen
JAJoe Alderman
Joe Alderman
CAClaire Argent
Claire Argent
SCSamuel Cusworth
Samuel Cusworth
KKKamlesh Khunti
Kamlesh Khunti

10 July 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
ZDZareen Deplano
Zareen Deplano
SCSamuel Cusworth
Samuel Cusworth
CDCarolyn Doree
Carolyn Doree
JGJames Griffin
James Griffin
NANicola Adderley
Nicola Adderley
JCJoht Singh Chandan
Joht Singh Chandan
Introduction: Stem cell transplant (SCT) is a potential cure for haematological malignancies whose outcomes are predicted to be poor on chemotherapy alone and cases difficult to treat using standard of care treatment. There is growing evidence to show that not all patients who would benefit from SCT receive it due to inequities in the treatment pathway. The role of socioeconomic deprivation on inequities in the SCT setting is unclear due to conflicting findings. We aim to synthesise the UK evidence base in this area from the point of diagnosis to transplant to guide further research and policy to improve survival for underserved patients. Method and analysis: Primary electronic searches will be performed in bibliographic databases including MEDLINE, Embase, Proquest Databases, Central & CDSR, Stem Cell Evidence and Web of Science and Google Scholar for grey literature. Eligibility criteria will include observational studies of UK patients diagnosed with haematological malignancies treated with SCT, where outcomes are reported according to socioeconomic deprivation. Two independent reviewers will screen each study and assess the quality of all included studies using the Newcastle-Ottawa grading system. Outcomes of interest include delay in diagnosis/referral, treatments/interventions received, referral to transplant, presence of comorbidities affecting transplant eligibility, transplant utilisation rates, waiting time to transplant and survival rates. Post-transplant outcomes are beyond the scope of this review. Inequities in SCT due to socioeconomic deprivation will be narratively summarised. Meta-analysis will be conducted dependent on data availability. This protocol has been registered with PROSPERO (2024: CRD42024620592). Ethics and dissemination: Ethical approval is not required for this study as it is a secondary analysis of published data. We are not aware of any ethical concerns regarding SCT or treatment of donors in the studies included in this research. This systematic review will retrieve, screen and extract data from UK research. SCT and the treatment of donors in the UK follow the National Health Service (NHS) and NHS Blood and Transplant guidelines and policies and are regulated by the Human Tissue Authority and Medicines and Healthcare Products Regulatory Agency. The data which will be used in this review will consist of data from NHS digital/NHS England or single NHS centre data, which will follow the guidelines and regulations above. The findings will be submitted for peer-reviewed publication, shared at conference presentations, and disseminated to both clinical and patient groups including National (Black, Asian, Mixed Race and Minority Ethnic) BAME Transplant Alliance and the National Institute for Health Research Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics. PROSPERO registration number: CRD42024620592.

18 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SCSamuel James Cusworth
Samuel James Cusworth
ZDZareen Deplano
Zareen Deplano
ADAlastair Denniston
Alastair Denniston
DBDavid Burns
David Burns
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar
JCJoht Singh Chandan
Joht Singh Chandan
Introduction: Haematological cancers are common in the UK, with a variety of morphologies. Stem cell transplants and chimeric antigen receptor (CAR) T-cell therapies provide significant options for hard to treat haematological cancers, although with difficult to predict outcomes. Research into the determinates of treatment efficacy, and access to treatments, is key to ensuring equal benefit across patients, and patient safety. With this, there are concerns about the small representation of minority groups in related research. We aim to report on the current knowledge, to guide future research. Methods and analysis: A variety of databases will be searched, for literature on UK minority ethnic populations receiving haematopoietic stem cell transplant or CAR T-cell therapy. Many outcomes will be analysed, covering the patient care pathway for those of the target population, although with a focus on follow-up after therapy. Plans have been made to conduct narrative synthesis, with meta-analysis where applicable. Ethics and Dissemination: Outputs will be published in an appropriate journal, and discussed with the wider NIHR Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics (BTRU) group. Discussions will also be undertaken with the BTRU patient partners group. Strengths and Limitations of this Study: This systematic review has a detailed search criteria with a variety of search tools, enabling high sensitivity in obtaining evidence. To enable this work to be completed, reviewers will be working independently on separate reference lists, during screening, rather than voting on the same references and resolving conflicts. To alleviate issues, reviewers will be first required to screen a defined number of papers together, using a more classical approach to confirm agreement, before working independently. Due to difficulties in pooling together international ethnic groups, only studies in the UK have been included, to reduce complexity. There are some ethnic groups which are more valid to pool together internationally than others, mainly in respect to genetic factors (as opposed to social), which this protocol does not consider.

19 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ZDZareen Deplano
Zareen Deplano
SCSamuel Cusworth
Samuel Cusworth
CDCarolyn Doree
Carolyn Doree
JGJames Griffin
James Griffin
NANicola J Adderley
Nicola J Adderley
JCJoht Singh Chandan
Joht Singh Chandan
Introduction Stem cell transplant (SCT) is a potential cure for haematological malignancies whose outcomes are predicted to be poor on chemotherapy alone and cases difficult to treat using standard of care treatment. There is growing evidence to show that not all patients who would benefit from SCT, receive it due to inequities in the treatment pathway. The role of socioeconomic deprivation on inequities in the SCT setting is unclear due to conflicting findings. We aim to synthesis the UK evidence base in this area to guide further research and policy to improve survival for underserved patients. Method and analysis Primary electronic searches will be performed in bibliographic databases including MEDLINE, Embase, Proquest Databases, Central & CDSR, Stem Cell Evidence and Web of Science and Google Scholar for grey literature. Eligibility criteria will include observational studies of UK patients diagnosed with haematological malignancies, treated with SCT, where outcomes are reported according to socioeconomic deprivation. Two independent reviewers will screen each study and assess the quality of all included studies be using the Newcastle-Ottawa grading system. Outcomes of interest include delay in diagnosis/referral, treatments/interventions received, referral to transplant, presence of co-morbidities affecting transplant eligibility, access to transplant, transplant utilisation rates, waiting time to transplant and survival rates. Inequities in SCT due to socioeconomic deprivation will be narratively summarised. Meta-analysis will be conducted dependent on data availability. This protocol has been registered with PROSPERO (2024: CRD42024620592). Ethics and dissemination Ethical approval is not required for this study as it is a secondary analysis of published data. The findings will be submitted for peer-reviewed publication, shared at conference presentations, and disseminated to both clinical and patient groups including National (Black, Asian, Mixed Race, and Minority Ethnic) BAME Transplant Alliance (NBTA) and the National Institute for Health Research (NIHR) Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics. Strengths and limitations of this study This review will provide the first comprehensive and systematic summary of inequities due to socioeconomic deprivation in the stem cell transplant setting in the UK, following the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines This review will focus on data collected from studies performed in a UK population only. The findings can be applied to a UK population but application to other countries will be limited. Patients and the public participated in the development of the review and will support interpretation of findings and dissemination to the wider public.